Wednesday, March 29, 2023
ClearPoint Neuro announced an exclusive multi-year licencing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialise a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance.
Under the terms of the agreement, the company will develop, obtain regulatory clearance, and commercialise the intracerebral cellular delivery device in key geographies. This partnership brings the innovative delivery platform to the pharmaceutical partners working on cellular therapy. When combined with ClearPoint system and software, cell delivery platform can potentially empower predicable and precise delivery of cells into different anatomical targets using various image-guidance technologies. This innovative approach will allow cellular delivery at facilities that do not have access to MRI and will also expedite therapeutic delivery and ultimately patient recovery.
This invention will help clinicians guide the delivery of biologic therapies — from stem cell transplants to gene therapy vectors — to specific locations in the human brain with real-time image guidance. By helping surgeons tailor biologic delivery to individual patient anatomy and specific diseases, this invention will contribute importantly to the successful treatment of neurological disorders such as Parkinson’s disease.
